Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler

Chest

Volumn 144, Issue 6, 2013, Pages 1795-1802

  Kosoglou, Teddy ^a   Hubbell, James ^a   Cutler, David L ^a   Johnson Levonas, Amy O ^a   Xu, Danlin ^a   Kantesaria, Bhavna S ^a   Kim, Kenneth ^b   Miller, S David ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WCCT Global   (United States)

^c Northeast Medical Research Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; HYDROCORTISONE; PLACEBO;

ADULT; AGED; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BACKACHE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MORNING DOSAGE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METERED DOSE INHALERS; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PREGNADIENEDIOLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890277363     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0505     Document Type: Article

References (14)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Disease website. http://www.goldcopd.org. Accessed May 24, 2013.
2. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR3): guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute website. http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.htm. Accessed January 9, 2013.
3. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2012;39(2):279-289.
4. Nathan RA, Nolte H, Pearlman DS; P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31(4):269-279.
5. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012;7:73-86.
6. ADVAIR HFA Inhalation Aerosol product label. GlaxoSmithKline website. http://us.gsk.com/products/assets/us-advair-hfa.pdf. Accessed February 4, 2013.
7. I. DULERA Inhalation Aerosol product label. Merck & Co website. http://www.merck.com/product/usa/pi-circulars/d/dulera/dulera-pi.pdf. 2013; Accessed February 4, 2013.
8. Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc. 2005;26(5):327-335.
9. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest. 2000;118(6):1538-1546.
10. Kosoglou T, Cutler DL, Staudinger H, Herron JM. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. Chest. 2010;137(1):115-121.
11. Kosoglou T, Hubbell J, Xuan F, et al. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:107-116.
12. Dweik RA, Boggs PB, Erzurum SC, et al American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615.
13. Jones SL, Herbison P, Cowan JO, et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002;20(3):601-608.
14. Nolte H, Pavord I, Backer V, et al. Dose-dependent antiinflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respir Med. 2013;107(5):656-664.